2014
New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Jürgensmeier JM, Eder JP, Herbst RS. New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs. Clinical Cancer Research 2014, 20: 4425-4435. PMID: 25183480, PMCID: PMC5369358, DOI: 10.1158/1078-0432.ccr-13-0753.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorClinical Trials as TopicGene Expression ProfilingHumansNeoplasmsPatient SelectionPrecision MedicineResearch DesignConceptsClinical trialsTumor biologyFuture patient selectionTherapy of patientsOngoing clinical evaluationBroad molecular profilingPromising tumor targetPersonalized medicinePatient selectionPatient populationTreatment recommendationsClinical evaluationTumor boardClinical studiesImmune parametersNovel agentsTumor targetsTreatment approachesSolid tumorsClinical researchPatientsMolecular profilingSpecific markersTumorsTrials
1989
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.
Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. Journal Of Clinical Oncology 1989, 7: 651-61. PMID: 2651580, DOI: 10.1200/jco.1989.7.5.651.Peer-Reviewed Original ResearchConceptsMaximum-tolerated doseAutologous bone marrow reinfusionAutologous bone marrow supportBone marrow reinfusionBone marrow supportMarrow reinfusionMarrow supportSystemic clearancePhase IConsiderable dose escalationRecurrent ovarian cancerPharmacokinetic studySevere ototoxicityToxicity consistingRenal dysfunctionDose escalationReversible hepatotoxicityContinuous infusionOvarian cancerActive drugHigh dosesLow dosesCarboplatinPatientsDoses